Condensed Consolidated Statements of Cash Flows $ in Thousands	6 Months Ended
	Jun. 30, 2025 USD ($)	Jun. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)
Cash flows from operating activities:
Net income (loss)	$ 5,117	$ (48,053)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	660	626
Inventory obsolescence	1,026	1
Stock-based compensation expense	42,672	26,825
Payment of Pharmakon PIK Interest	(5,492)	0
Non-cash interest expense on royalty financing obligations	26,916	28,450
Non-cash interest expense on secured term loan and amortization of debt issuance costs	1,003	10,591
Amortization of discount on investments, net	(2,533)	(6,674)
Loss on extinguishment of debt	4,171	0
Changes in operating assets and liabilities:
Increase in receivables	(21,295)	(12,085)
Decrease (increase) in inventory	568	(481)
Decrease in prepaid expenses and other assets	28	2,851
Decrease in royalty financing obligations	(36,921)	(33,069)
Decrease in accounts payable and accrued expenses	(2,135)	(24,034)
Net cash provided by (used in) operating activities	13,785	(55,052)
Cash flows from investing activities:
Acquisitions of property and equipment	(322)	(390)
Purchases of investments	(78,103)	(200,303)
Sales and maturities of investments	134,647	227,000
Net cash provided by investing activities	56,222	26,307
Cash flows from financing activities:
Net proceeds from common stock issued under stock-based compensation plans	5,811	1,945
Common stock issued to directors in lieu of cash retainer	15	23
Repayment of Pharmakon term loan principal	(69,508)	0
Prepayment premium and fees on Pharmakon term loan	(2,250)	0
Principal payments on royalty financing obligations	(3,956)	0
Withholding taxes paid on stock-based awards	(2,217)	(4,190)
Principal payments on finance lease liabilities	(1,052)	(792)
Net cash used in financing activities	(73,157)	(3,014)
Effect of exchange rates on cash, cash equivalents and restricted cash	1,810	(483)
Net decrease in cash, and cash equivalents, and restricted cash	(1,340)	(32,242)
Less: net increase in cash and cash equivalents classified within current assets held for sale	(15,058)	0
Net decrease in cash, and cash equivalents, and restricted cash	(16,398)	(32,242)
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation			$ 112,447
Cash, cash equivalents and restricted cash at end of period	89,925	80,205
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract]
Cash and cash equivalents	88,033	78,410
Restricted cash	492	1,795
Restricted cash in other assets	1,400	0
Total cash, cash equivalents and restricted cash	89,925	80,205
Supplemental Cash Flow Information [Abstract]
Cash paid for interest	16,679	10,041
Cash paid for taxes	1,228	865
Purchases of property and equipment included in accounts payable	1,069	0
Taxes withheld on stock-based awards included in accrued expenses	$ 343	$ 189